Minimal phenotype panels - A method for achieving maximum population coverage with a minimum of HLA antigens

Human Immunology

Volumn 51, Issue 2, 1996, Pages 95-98

  Schipper, R F ^a,b   Van Els, C A C M ^a,b   D'Amaro, J ^a,b   Oudshoorn, M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; CAUCASIAN; GENE FREQUENCY; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNOGENETICS; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL;

EPITOPES; GENE FREQUENCY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0030464098     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(96)00138-3     Document Type: Article

References (12)

1. 1. Watari E, Dietzschold B, Szokan G, Heber-Katz E: A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2. J Exp Med 165:459, 1987.
2. 2. Kast WM, Melief CJM: Fine peptide specificity of cytotoxic T lymphocytes directed against Adenovirus induced tumors and peptide-MHC binding. Int J Cancer (Suppl 6):90, 1991.
3. 3. Schulz M, Zinkernagel RM, Hengartner H: Peptide-induced antiviral protection by cytotoxic T cells. Proc Natl Acad Science 88:991, 1991.
4. 4. Reinholdsson-Ljunggren G, Ramqvist T, Ahrlund-Richter L, Dalianis T: Immunization against polyoma tumors with synthetic peptides derived from the sequences of middle-and large-T antigens. Int J Cancer 50:142, 1992.
5. 5. Feltkamp MCW, Smits HL, Vierboom MP, Minnaar RP, De Jongh BM, Drijfhout JW, Schegget J, Melief CJM, Kast WM: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242, 1993.
6. 6. Schumacher TNM, Van Bleek GM, Heemels M, Deres K, Li KW, Imarai M, Vernie LN, Nathenson SG, Ploegh HL: Synthetic peptide libraries in the determination of T cell epitopes and peptide binding specificity of class 1 molecules. Eur J Immunol 22:1405, 1992.
7. 7. Van der Burg SH, Klein MR, Van de Velde CJH, Kast WM, Miedema F, Melief CJM: Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase. AIDS 9:121, 1995.
8. 8. Fast PE, Walker MC: Human trials of experimental AIDS vaccines. AIDS 7:S147, 1993.
9. 9. Bleek GM, Nathenson SG: Peptide presentation by major histocompatibility class I molecules. Chem Immunol 57: 1, 1993.
10. 10. Lagaay AM, D'Amaro J, Ligthart GJ, Schreuder GMT, Rood JJv, Hijmans W: Longevity and heredity in humans: association with the human leucocyte antigen phenotype. In Pierpaoli W, Fabris N (eds): Physiological Senescence and Its Postponement. New York, The New York Academy of Sciences, 1991.
11. 11. Yasuda N, Kimura M: A gene-counting method of maximum likelihood for estimating gene frequencies in ABO and ABO-like systems. Ann Hum Genet 31:409, 1968.
12. 12. Tanigaki N, Fruci D, Chersi A, Falasca G, Tosi R, Butler RH: HLA-A2-Binding peptides cross-react not only within the A2 subgroup but also with other HLA-A locus allelic products. Hum Immunol 39:155, 1994.